Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.78 |
| ▸ | HTR3A | P46098 | 1/20 | 0.78 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908050 | 0.91 | CHRNA7 (0.89) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL7559030 | 0.88 | CHRNA7 (1.00) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL5914683 | 0.87 | CHRNA7 (0.78) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL7556010 | 0.86 | CHRNA7 (0.71) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL5914749 | 0.85 | CHRNA7 (0.74) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL5914659 | 0.83 | CHRNA7 (0.71) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL5914655 | 0.83 | CHRNA7 (0.71) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL5914755 | 0.83 | CHRNA7 (0.71) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL7554342 | 0.83 | CHRNA7 (0.71) | CHRNA7HTR3ACHRNA3 | |
| SCHEMBL5914691 | 0.83 | CHRNA7 (0.71) | CHRNA7HTR3ACHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075983-A1 | Novel Diazabicycloalkane Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | claimed |
| US-20060014750-A1 | Pharmaceutical compositions for the treatment of CNS and other disorders | PFIZER INC | 2006-01-19 | — | — | US | claimed |
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | PFIZER INC. | 2002-11-28 | — | — | US | claimed |
| EP-1231212-A1 | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | claimed |
| US-20090075983-A1 | Novel Diazabicycloalkane Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | disclosed |
| US-20060014750-A1 | Pharmaceutical compositions for the treatment of CNS and other disorders | PFIZER INC | 2006-01-19 | — | — | US | disclosed |
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | PFIZER INC. | 2002-11-28 | — | — | US | disclosed |
| EP-1231212-A1 | Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders | Pfizer Products Inc. (US) | 2002-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177591-A1 | Pharmaceutical compositions for the treatment of CNS and other discorders | CHRNA7, CHRNA5, CHRNA10 | CHRNA7 1/4885HTR3A 98/4885CHRNA3 4/4885 |
| US-20060014750-A1 | Pharmaceutical compositions for the treatment of CNS and other disorders | CHRNA7, CHRNA10, CHRNA5 | CHRNA7 1/4885HTR3A 145/4885CHRNA3 6/4885 |
| US-20090075983-A1 | Novel Diazabicycloalkane Derivatives and Their Medical Use | CHRNA6, CHRNA2, CHRNA7 | CHRNA7 3/4885HTR3A 165/4885CHRNA3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.